## Abstract Since androgen receptor (AR) plays an important role in prostate cancer development and progression, androgenβablation has been the frontline therapy for treatment of advanced prostate cancer even though it is rarely curative. A curative strategy should involve functional and structural
Differential transactivation by the androgen receptor in prostate cancer cells
β Scribed by Snoek, Robert; Bruchovsky, Nicholas; Kasper, Susan; Matusik, Robert J.; Gleave, Martin; Sato, Naohide; Mawji, Nasrin R.; Rennie, Paul S.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 232 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
The purpose of this study was to determine the contribution of different transactivating regions of the androgen receptor (AR) to the induction of androgen-regulated promoters in poorly (PC3 cells) and well-differentiated (LNCaP cells) prostate cancer cell lines. METHODS. PC3 and LNCaP cells were co-transfected with plasmids expressing full-length AR or deletion mutants together with luciferase reporters linked to the probasin (PB) and PSA promoters; as well as to ARR 3 tk, a PB-derived recombinant promoter. RESULTS. Androgen induction of the ARR 3 tk promoter in the presence of AR was 8-to 10-fold higher than that seen with the PB promoter. Activation of ARR 3 tk was greatest with an androgen-independent construct in which the first 231 amino acids and the ligand binding domain had been removed, indicating that this promoter is more responsive to activating functions in the N-terminal domain than in the ligand binding domain. By comparison, induction of the PB promoter was greatest with the full-length AR, which suggests that the ligand binding domain also makes a major contribution to the activation of this promoter. In similar analyses with the PSA promoter, AR regions required for promoter induction was dependent on the host cell type. In PC3 cells, the predominant AR transactivation function was androgen-independent and resided in the N-terminal domain, whereas in LNCaP cells, the highest level of induction was androgen dependent and also required participation of the ligand binding domain. CONCLUSIONS. Our results indicate that the relative utilization of transactivating functions in N-terminal and ligand binding domains of the AR is promoter and cell specific.
π SIMILAR VOLUMES
## Abstract We have shown recently that inhibition of androgen receptor (AR) expression with an antisense AR oligonucleotide (ODN) inhibits LNCaP prostate tumor cells in vitro as well as in vivo. In this study, we investigated gene expression changes that occur after AR signaling blockade, either t
## Abstract To study the mechanisms whereby androgenβdependent tumors relapse in patients undergoing androgen blockade, we developed a novel progression model for prostate cancer. The PC346C cell line, established from a transurethral resection of a primary tumor, expresses wildβtype (wt) androgen
Progression to androgen independence remains the main problem that impacts on survival and quality of life in prostate cancer patients. We have investigated the potency of tributyrin, an orally available prodrug of butyrate, to induce growth arrest, differentiation and apoptosis in LNCaP, PC-3 and T